3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
3
Plasma cell
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
76
Triple Negative Breast Neoplasms
12
Ovarian Neoplasms
7
Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms, Male
4
Pancreatic Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Mycosis Fungoides
1
Melanoma
1
Interventions
Docetaxel
2
liposomal doxorubicin
1
entinostat
1
Thalidomide
1
SUB1 protein, human
1
Gemcitabine
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AIDS-related Kaposi sarcoma
×
liposomal doxorubicin
×
Breast
×
Clear all
NCT05567601
2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1
Completed
36 enrolled